Although varicella vaccine is given to clinically stable human immunodeficiency virus (HIV)-infected children, its effectiveness is unknown. We assessed its effectiveness by reviewing the medical records of closely monitored HIV-infected children, including those receiving highly active antiretroviral therapy (HAART) between 1989 and 2007. Varicella immunization and development of varicella or herpes zoster were noted. Effectiveness was calculated by subtracting from 1 the rate ratios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children. The effectiveness of the vaccine was 82% (95% confidence interval [CI], 24%-99%; ) against varicella and was 100% P p .01 (95% CI, 67%-100%; ) against herpes zoster. When P ! .001 the analysis was controlled for receipt of HAART, vaccination remained highly protective against herpes zoster.
fection in both healthy and certain immunocompromised children [2] . On the basis of clinical trials, 2 doses of varicella vaccine 2 months apart were recommended in 1999 for relatively healthy HIV-infected children with CD4 cell percentages у25% [3] . Later, children with CD4 cell percentages у15% were safely vaccinated [4] . Although the vaccine is widely used, there is no published information, to our knowledge, on its effectiveness in these children [5, 6] . Therefore, we assessed the effectiveness of varicella vaccine in preventing varicella and herpes zoster in this population.
Methods. We conducted a longitudinal cohort study with clinical data collected from 2 units of the Pediatric AIDS Clinical Trials Group: Columbia University-New York Presbyterian Hospital and St. Jude Children's Research Hospital. This study was approved by both institutional review boards.
The medical records of 164 perinatally HIV-infected children from between 1989 and 2007 were reviewed to determine whether and when they had received varicella vaccine, developed varicella, and/or developed herpes zoster. All perinatally HIV-infected children were included except for those who developed varicella before 1 year of age, because varicella vaccine is not given before then. Vaccine was offered to children on the basis of the recommendations of the Centers for Disease Control and Prevention at the time.
Varicella was defined as an illness with a generalized pruritic vesicular rash with fever, diagnosed by a clinician. Herpes zoster was defined as an illness with a unilateral vesicular rash in a dermatomal distribution without another identifiable cause. Laboratory confirmation of VZV infection was usually not obtained. Immunized children received at least 1 dose of live attenuated varicella vaccine. Highly active antiretroviral therapy (HAART) was defined as receipt of у3 antiretroviral agents, including 2 nonnucleoside reverse-transcriptase inhibitors and either a protease inhibitor or a nucleoside reverse-transcriptase inhibitor. Herpes zoster that occurred within 6-8 weeks after initiation of HAART was considered to be a possible instance of immune reconstitution inflammatory syndrome (IRIS).
The statistical significance of differences in baseline characteristics between groups being compared was assessed with the x 2 test for categorical variables and with the t test for continuous variables. All follow-up times were calculated in person-years (PYs). Rate ratios, their associated 95% confidence intervals (CIs), and their statistical significance (2-tailed P р ) were calculated using PEPI software [7] . The effectiveness .05 of the vaccine was calculated as 1 minus the rate ratio. Incidence rates of varicella were calculated for 2 periods: the prevaccine era for HIV-infected children (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) , when none of the children received varicella vaccine) and the vaccine era (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . For unvaccinated subjects, time 0 was defined as 1 year of age, and the end point for time at risk (when they were censored from the denominator) was either the occurrence of varicella, receipt of varicella vaccine, or the last clinic visit. For vaccinated patients, time 0 was defined as the date they received varicella vaccine. Vaccinated subjects were censored at either onset of breakthrough varicella or the date of the last clinic visit.
Because herpes zoster results from reactivation of a latent infection, only individuals previously infected with VZV through either natural disease or varicella vaccine were analyzed to assess the vaccine's effectiveness against herpes zoster [8] . Time 0 was defined as either the date of immunization or the date of onset of varicella; subjects were censored at onset of herpes zoster or the last clinic visit. In the patients who developed natural varicella, herpes zoster incidence rates were calculated for 2 periods: the prevaccine era (1989-1998) and the vaccine era (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . Rate ratios for development of herpes zoster among children who had been immunized versus those who had varicella were calculated.
The incidence rates and incidence rate ratio for herpes zoster were also calculated for patients at risk of developing herpes zoster among only those who were receiving HAART (to control for the possibility that HAART alone might decrease the risk of herpes zoster). Time 0 was defined as the date when the patients both had varicella (or had received varicella vaccine) and were also receiving HAART. Censoring occurred at the date of either the onset of herpes zoster or the last clinic visit.
Results. Half of the subjects were female, and 63% were non-Hispanic African Americans. Of 72 vaccinated children, 39 (54%) had received 2 doses of vaccine. The baseline characteristics (such as CD4 cell counts) of patients who developed varicella, received varicella vaccine, and/or developed herpes zoster were similar and not statistically significantly different (Table 1) . During the prevaccine era, only 6% of unvaccinated patients were receiving HAART at the onset of varicella; after 1998, in contrast, 63% were receiving HAART when they contracted varicella. Of the 32 patients who developed herpes zoster after varicella, 15 (47%) were receiving HAART (60% during the HAART era). Of the vaccinated patients, 85% were receiving HAART when immunized. None developed herpes zoster.
Among unvaccinated children, 83 cases of varicella occurred. During the prevaccine era (before 1999), the incidence was 64 cases per 619 PYs (103. 3 Table 2 ). This was not significantly different from the incidence of herpes zoster during the pre-HAART era ( ). The median time between varicella P p .49 and herpes zoster was 4.1 years during the pre-HAART era and 4.8 years during the HAART era.
The 72 HIV-infected children who were vaccinated were followed up for a total of 298 PYs, and there were no cases of herpes zoster (0 cases per 1000 PYs [95% CI, 0-12.2 cases per 1000 PYs]); neither of the 2 children who had breakthrough varicella developed herpes zoster. The median duration of follow-up after immunization was 4.4 years. The vaccine's effectiveness against herpes zoster was 100% (95% CI, 67%-100%; ) ( Table 2) .
Sixty unvaccinated patients who were receiving HAART and who had varicella were followed up for 344 PYs. Fifteen patients developed herpes zoster (at a median of 6.5 years after the initiation of HAART), an incidence of 43.6 cases per 1000 PYs (95% CI, 24.4-71.9 cases per 1000 PYs). When the 3 children with possible IRIS herpes zoster were excluded, the incidence of herpes zoster was 12 cases per 344 PYs (34.9 cases per 1000 PYs [95% CI, 18.0-60.9 cases per 1000 PYs]). Of the 65 vaccinated children who were receiving HAART, none developed herpes zoster (0 cases per 1000 PYs [95% CI, 0-15.3 cases per 1000 PYs]; median duration of follow-up after initiation of HAART, 4 years). The vaccine's effectiveness against herpes zoster among these children overall was 100% (95% CI, 63%-100%;
); the 95% CI was 54%-100% when children with P ! .01 possible IRIS were excluded ( ) (Table 2 ). P ! .01 Discussion. Before 1999, VZV infections (particularly herpes zoster) were frequent causes of morbidity among HIVinfected children. Varicella vaccine was recommended for HIVinfected children on the basis of safety and immunogenicity, but its efficacy in these children was not evaluated [3, 5, 6] . Our study indicates that varicella vaccine protects against both varicella and herpes zoster. There was a 63% decrease in the incidence of varicella among unvaccinated children after 1999, likely a result of herd immunity from widespread use of vaccine. Despite the lower attack rate of varicella during the vaccine era, however, we were still able to show that immunization was highly protective in HIV-infected children.
Immunization also protected HIV-infected children against herpes zoster. The Oka vaccine strain can establish latent infection and can reactivate; protection from herpes zoster is probably not entirely related to the Oka strain itself. It is possible that protection against herpes zoster is due to the relatively normal immune function of vaccine recipients when they are immunized [1, 9] ; this may result only in the development of rare skin rashes after vaccination, which in turn correlates with a lower risk of subsequent development of herpes zoster [10] .
The incidence of herpes zoster may increase transiently after the initiation of HAART [11, 12] , which is often attributed to IRIS. To account for the possibility that some of the cases of herpes zoster could be attributed to "immune reconstitution," we excluded these cases in one of our analyses. Even when we excluded 3 cases of herpes zoster that developed within 6-8 weeks after the initiation of HAART, the vaccine was still statistically significantly effective in preventing herpes zoster.
HAART was used more frequently after 1997, improving immune function, the quality of life, and survival rates among HIVinfected children. In one report, the introduction of HAART decreased the incidence of herpes zoster by 50% among HIV-infected children [13] . In that study, however, vaccinated children and those with natural varicella were analyzed together. Another study indicated that even during the HAART era herpes zoster remained a significant cause of morbidity among unvaccinated HIV-infected children [14] . In a different study of HIV-infected children, it was not possible to determine whether a decrease in herpes zoster was attributable to immunization or to HAART [15] . In the present study, by assessing the incidence rates of herpes zoster only among children receiving HAART (vaccinated children and unvaccinated children who had had varicella) we found varicella vaccine to be highly effective in preventing herpes zoster, even when children with possible IRIS were excluded from the analysis. Therefore, varicella vaccine rather than HAART appears to be the major factor in the reduction in herpes zoster among immunized patients.
It also did not appear to be the case that the vaccine's effectiveness could be explained by the vaccinated children having better overall immunity than the unvaccinated children. The median CD4 cell percentages for the unvaccinated and unvaccinated groups were similar, suggesting that minimal immunosuppression existed in both groups.
There are several possible limitations to this study. Our study was observational and not a randomized clinical trial; data were obtained by review of medical records. The diagnoses of VZV infection were not laboratory verified. The HIV-infected children included in our study, however, were intensively and prospectively followed up under study conditions of the Pediatric AIDS Clinical Trials Group, and the data are therefore of high quality.
Regarding protection against herpes zoster, the median age of the vaccinated group was lower than that of the unvaccinated group. Younger children were less likely to have already had varicella and were more likely to have been immunized, compared with older children. However, there is evidence that the age at the time of primary infection with VZV (except among children !1 year of age) is unrelated to the risk of herpes zoster, unlike that in adults [2] .
In summary, our data show that varicella vaccine was highly effective in preventing varicella and herpes zoster in a cohort of perinatally HIV-infected children followed up between 1989 and 2007. Additional follow-up over a longer period with larger numbers of subjects may be useful to confirm our findings.
